September 29, 2020   English | عربي
Add to Twitter
Phase III InPedILD™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung disease
• First-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globally • This new study builds on the Phase III INBUILD® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype1,2,3 • Global Phase III multicentre clinical trial is planned to be conducted in approximately 70 sites in 24 countries
News Agencies Feed